Underlying analysis of pharma-based structured products amid a challenging economic climate shows falling sales and issuance.

The global 2020 pandemic placed the limelight on the pharmaceutical industry as a very timely source of innovation. However, several fundamental challenges could undermine future prospects for the industry, including logistics around the administration of the various vaccination programmes. The SRP database shows that issuance of primary market products linked to pharma companies in 2020, at 8,102 , dropped by 34%. When we take all into account all structured products tied to pharma companies –

Continue reading with a subscription to the SRP market intelligence platform.

Request Demo

Already a subscriber? Login